Osteogenesis Imperfecta

Overview

Osteogenesis imperfecta (OI), often called brittle bone disease, is a group of inherited disorders in which bones break unusually easily, sometimes with little or no injury. Most cases involve changes in genes affecting type I collagen, a major protein that gives bone strength; symptoms range from a few fractures over a lifetime to fractures before birth, severe bone deformity, short stature, scoliosis, dental problems, hearing loss, and breathing complications. NIAMS overview

OI affects people of all sexes and ancestries and may be inherited or arise from a new genetic change in the affected person. Prognosis is highly variable: mild forms can allow near-typical life expectancy and independence, while the most severe forms can cause life-threatening complications around birth or from chest and spine disease. There is no approved cure. Current care is multidisciplinary and aims to prevent fractures and disability through rehabilitation, fracture and orthopedic care—including intramedullary rods for deforming long bones when needed—and medicines such as bisphosphonates to increase bone density. GeneReviews management

Scope of Recent Research (2020–present)

Research since 2020 has been active across disease-modifying bone medicines, stem-cell approaches, and increasingly precise genetic therapies. The central challenge is that OI is genetically diverse: a treatment that strengthens bone may help across several forms, whereas a true cure must safely correct or neutralize the causal mutation in enough bone-forming cells. The field has produced important animal and cell-model results, but no gene- or cell-based therapy has yet demonstrated a durable cure in people. Emerging therapeutic landscape

Major Breakthroughs and Emerging Therapies

The most explicitly curative strategy is genetic correction. In 2023–2024, investigators at UMass Chan Medical School reported an adeno-associated virus (AAV) system that delivered CRISPR-Cas9 gene editing machinery and a repair template to bone-forming cells in a mouse model of severe dominant OI caused by a Col1a2 mutation. Treated mice showed improved bone mass, mineralization, architecture, skeletal deformity, grip strength, and spontaneous-fracture outcomes. This was an important proof of concept for repairing a collagen mutation directly in living bone, but it remains a mouse experiment rather than a human treatment. AAV-based collagen gene editing

A complementary precision-medicine route uses induced pluripotent stem cells (iPSCs)—adult cells reprogrammed into stem-like cells—from people with OI. A 2021 study corrected a mutated COL1A1 gene with CRISPR/Cas9 in patient-derived iPSCs and restored osteoblast, or bone-forming-cell, differentiation in laboratory experiments. Such work is valuable for testing mutation-specific therapies and may eventually support autologous cell replacement, but producing, editing, validating, and safely engrafting enough corrected cells remains a major hurdle. CRISPR correction in patient-derived cells

Mesenchymal stromal cells (MSCs), cells that can support bone formation and release growth-promoting signals, are another experimental approach. In the small TERCELOI pediatric study, repeated MSC infusions were reported to be safe and associated with improved bone measures and quality of life during treatment and follow-up; the investigators also found evidence consistent with a temporary pro-bone-forming paracrine effect, meaning benefits may come largely from signals released by the cells rather than permanent replacement of defective bone cells. TERCELOI MSC trial The ongoing BOOSTB4 program is testing repeated fetal MSC administration before and/or after birth for severe OI, but it is an exploratory early-phase study rather than established therapy. BOOSTB4 protocol

The most advanced medicines are not cures but may substantially improve skeletal strength. Setrusumab is an antibody that blocks sclerostin, a natural brake on bone formation. In the phase 2b ASTEROID study in adults with OI types I, III, and IV, 12 months of treatment increased bone-formation markers and lumbar-spine bone density; fracture rates were numerically low in the highest-dose group, but the study was small and not designed to give a definitive answer on fracture reduction. ASTEROID phase 2b results Anti-transforming growth factor-beta (TGF-β) therapy with fresolimumab has also completed a small safety-focused study, reflecting a parallel strategy to correct abnormal bone-remodeling signaling rather than the underlying mutation. Fresolimumab study results

Clinical Trials and Experimental Approaches

Ultragenyx’s setrusumab ORBIT study, NCT05125809, is an operationally seamless phase 2/3 randomized trial in children and adults with OI. The registry listed the study as active but not recruiting, with 183 enrolled participants, actual primary completion on October 20, 2025, and estimated final completion in April 2027; its phase 3 outcomes include radiographically confirmed fracture rate, lumbar-spine bone density, physical function, pain, and safety. As of the most recently posted registry update, no trial results were posted. ORBIT setrusumab trial

Amgen is recruiting for a phase 3 trial of romosozumab, another sclerostin-blocking antibody, versus bisphosphonates in ambulatory children and adolescents with OI. The trial plans to enroll 106 participants and measures clinical fractures, all fractures, bone density, and safety; primary completion is estimated for June 2027. Pediatric romosozumab phase 3 trial Earlier pediatric romosozumab work evaluated dosing, drug levels, immune responses, bone-turnover markers, and lumbar-spine bone density rather than proving fracture prevention. Pediatric romosozumab study

Cell therapy remains early stage. Emory University has registered a single-site phase 1/2 study of third-party bone-marrow-derived MSCs for children aged 3–10 years with type III OI; the study is designed to assess infusion safety, growth, and bone health and was listed as not yet recruiting in its May 2026 registry update. Emory MSC phase 1/2 study

Methodologies and Scientific Approaches

Researchers combine genetically defined mouse models, patient-derived cells, imaging, and clinical natural-history data. Mouse models carrying disease-causing collagen variants allow investigators to measure fracture frequency, bone structure by micro-computed tomography, mineralization, and mechanical strength after gene editing or drug treatment. The AAV-CRISPR study illustrates the importance of delivering treatment to osteoblast-lineage cells throughout the skeleton and measuring both molecular correction and whole-animal functional outcomes. AAV-based collagen gene editing

Clinical studies increasingly pair fracture outcomes with dual-energy X-ray absorptiometry (DXA) bone-density scans, bone-turnover biomarkers such as P1NP and CTX, radiographic vertebral assessment, physical-function measures, pain scales, and quality-of-life instruments. Longitudinal studies are also essential because OI severity, fracture risk, and treatment response differ substantially by age and genetic cause. ORBIT setrusumab trial Brittle Bone Disorders Consortium

Leading Institutions and Funding

UMass Chan Medical School, including its Horae Gene Therapy Center, is a leading site for mutation-correction research, with investigators reporting AAV-mediated CRISPR editing in an OI mouse model. The National Institute of Arthritis and Musculoskeletal and Skin Diseases funded Tadatoshi Sato’s “Precision Gene Editing on Osteogenesis Imperfecta” project at UMass with $165,825 in fiscal year 2025; the project period runs from September 2024 through August 2026. NIH precision gene-editing award AAV-based collagen gene editing

Clinical and translational infrastructure is led in part by the NIH Rare Diseases Clinical Research Network’s Brittle Bone Disorders Consortium, headquartered at Baylor College of Medicine and involving multiple North American centers. Its program includes natural-history, biomarker, growth, dental, and clinical-intervention research across genetic bone-fragility disorders. Brittle Bone Disorders Consortium The Osteogenesis Imperfecta Foundation supports workforce development and patient-centered research; its Michael Geisman Fellowship can provide up to $50,000 per year for up to two years to postdoctoral OI researchers. OI Research Fund

Strengths, Limitations, and Challenges

The field’s main strength is that it is attacking OI at several levels: medicines can improve bone formation now, cell therapies may provide supportive biological signals, and gene editing directly addresses the causal mutation. The mouse AAV-CRISPR results are particularly encouraging because they improved multiple disease features rather than only bone density. However, a mouse-model rescue does not establish safety, delivery efficiency, durability, or effectiveness in humans. AAV-based collagen gene editing

The central limitations are biological and practical. OI involves more than 20 known genes and many mutation types, so a repair system may need to be individualized or broadly adaptable. For dominant collagen mutations, simply adding a healthy gene may not be enough because the harmful collagen can still be produced. AAV gene delivery can provoke immune responses, may be difficult to repeat, and must reach a large number of bone-forming cells without problematic off-target editing. Cell therapies face uncertain long-term engraftment, possible immune barriers, manufacturing complexity, and limited evidence from very small studies. Meanwhile, bone-building antibodies and bisphosphonates can improve skeletal measures but do not repair the defective gene or remove the need for lifelong specialist care. Emerging therapeutic landscape GeneReviews management

Outlook and Future Directions

As of August 8, 2026, OI is not close to a broadly available cure, but the path toward one is clearer than it was at the start of the decade. The most important milestones to watch are publication of controlled fracture-outcome data from setrusumab and romosozumab trials; safety and durability results from repeated MSC trials; and replication of AAV-CRISPR correction in additional OI models, followed by evidence that editing can be delivered safely and efficiently to human skeletal cells. A first mutation-specific genetic therapy could become plausible for selected forms of OI before a universal cure, but substantial preclinical safety, delivery, manufacturing, and clinical-trial work remains necessary. ORBIT setrusumab trial Pediatric romosozumab phase 3 trial AAV-based collagen gene editing

References

• NIAMS overview — National Institute of Arthritis and Musculoskeletal and Skin Diseases, 2022.
• GeneReviews management — GeneReviews, 2025.
• Emerging therapeutic landscape — Sun et al., 2024.
• AAV-based collagen gene editing — Yang et al., 2024.
• CRISPR correction in patient-derived cells — Chen et al., 2021.
• TERCELOI MSC trial — Infante et al., 2021.
• BOOSTB4 protocol — Sagar et al., 2024.
• ASTEROID phase 2b results — Glorieux et al., 2024.
• Fresolimumab study results — Baylor College of Medicine, 2024.
• ORBIT setrusumab trial — Ultragenyx Pharmaceutical, 2026.
• Pediatric romosozumab phase 3 trial — Amgen, 2026.
• Pediatric romosozumab study — Amgen, 2026.
• Emory MSC phase 1/2 study — Emory University, 2026.
• NIH precision gene-editing award — National Institutes of Health, 2025.
• Brittle Bone Disorders Consortium — National Institutes of Health, 2024.
• OI Research Fund — Osteogenesis Imperfecta Foundation, 2026.